Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets

Frontiers in Pharmacology

Volumn 6, Issue FEB, 2015, Pages

  Pastor Anglada, Marçal ^a,b   Pérez Torras, Sandra ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biomarker; Cancer; ENT1; Nucleoside analog; Nucleoside transporter; Viral diseases

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEIN; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 2; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; NUCLEOSIDE ANALOG; NUCLEOSIDE TRANSPORTER; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PURINE NUCLEOSIDE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; GENE; GENETIC HETEROGENEITY; HUMAN; INFLAMMATORY DISEASE; NEOPLASM; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCL28 GENE; SLC29 GENE; VIRUS INFECTION;

EID: 84926452313     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00013     Document Type: Article

References (163)

1. Arimany-Nardi, C., Errasti-Murugarren, E., Minuesa, G., Martinez-Picado, J., Gorboulev, V., Koepsell, H.,et al. (2014). Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Br. J. Pharmacol. 171, 3868-3880. doi: 10.1111/bph.12748
2. Avitan-Hersh, E., Mandel, H., Indelman, M., Bar-Joseph, G., Zlotogorski, A., and Bergman, R. (2011). A case of H syndrome showing immunophenotye similarities to Rosai-Dorfman disease. Am. J. Dermatopathol. 33, 47-51. doi: 10.1097/DAD.0b013e3181ee547c
3. Aymerich, I., Foufelle, F., Ferre, P., Casado, F. J., and Pastor-Anglada, M. (2006). Extracellular adenosine activates AMP-dependent protein kinase (AMPK). J. Cell Sci. 119, 1612-1621. doi: 10.1242/jcs.02865
4. Badagnani, I., Chan, W., Castro, R. A., Brett, C. M., Huang, C. C., Stryke, D.,et al. (2005). Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 5, 157-165. doi: 10.1038/sj.tpj.6500303
5. Baldwin, S. A., Beal, P. R., Yao, S. Y., King, A. E., Cass, C. E., and Young, J. D. (2004). The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 447, 735-743. doi: 10.1007/s00424-003-1103-2
6. Baldwin, S. A., Yao, S. Y., Hyde, R. J., Ng, A. M., Foppolo, S., Barnes, K.,et al. (2005). Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J. Biol. Chem. 280, 15880-15887. doi: 10.1074/jbc. M414337200
7. Bar, F., Sina, C., and Fellermann, K. (2013). Thiopurines in inflammatory bowel disease revisited. World J. Gastroenterol. 19, 1699-1706. doi: 10.3748/wjg.v19.i11.1699
8. Barnes, K., Dobrzynski, H., Foppolo, S., Beal, P. R., Ismat, F., Scullion, E. R.,et al. (2006). Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ. Res. 99, 510-519. doi: 10.1161/01.RES.0000238359.18495.42
9. Bhutia, Y. D., Hung, S. W., Patel, B., Lovin, D., and Govindarajan, R. (2011). CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 71, 1825-1835. doi: 10.1158/0008-5472.CAN-10-2736
10. Bolze, A., Abhyankar, A., Grant, A. V., Patel, B., Yadav, R., Byun, M.,et al. (2012). A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant. PLoS ONE 7:e29708. doi: 10.1371/journal.pone.0029708
11. Borbath, I., Verbrugghe, L., Lai, R., Gigot, J. F., Humblet, Y., Piessevaux, H.,et al. (2012). Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur. J. Cancer 48, 990-996. doi: 10.1016/j.ejca.2011.11.006
12. Burckhardt, G. (2012). Drug transport by organic anion transporters (OATs). Pharmacol. Ther. 136, 106-130. doi: 10.1016/j.pharmthera.2012.07.010
13. Cano-Soldado, P., Gorraitz, E., Errasti-Murugarren, E., Casado, F. J., Lostao, M. P., and Pastor-Anglada, M. (2012). Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket. Am. J. Physiol. Cell Physiol. 302, C257-C266. doi: 10.1152/ajpcell.00198.2011
14. Cano-Soldado, P., Lorrayoz, I. M., Molina-Arcas, M., Casado, F. J., Martinez-Picado, J., Lostao, M. P.,et al. (2004). Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir. Ther. 9, 993-1002.
15. Cano-Soldado, P., and Pastor-Anglada, M. (2012). Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med. Res. Rev. 32, 428-457. doi: 10.1002/med.20221
16. Cheng, Y., Vapurcuyan, A., Shahidullah, M., Aleksunes, L. M., and Pelis, R. M. (2012). Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug. Metab. Dispos. 40, 617-624. doi: 10.1124/dmd.111.042036
17. Cihlar, T., Ho, E. S., Lin, D. C., and Mulato, A. S. (2001). Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20, 641-648. doi: 10.1081/NCN-100002341
18. Cihlar, T., Lin, D. C., Pritchard, J. B., Fuller, M. D., Mendel, D. B., and Sweet, D. H. (1999). The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56, 570-580. doi: 10.1124/mol.56.3.570
19. Clarke, M. L., Damaraju, V. L., Zhang, J., Mowles, D., Tackaberry, T., Lang, T.,et al. (2006). The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine. Mol. Pharmacol. 70, 303-310. doi: 10.1124/mol.105.021543
20. Cliffe, S. T., Kramer, J. M., Hussain, K., Robben, J. H., de Jong, E. K., de Brouwer, A. P.,et al. (2009). SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway. Hum. Mol. Genet. 18, 2257-2265. doi: 10.1093/hmg/ddp161
21. Coothankandaswamy, V., Elangovan, S., Singh, N., Prasad, P. D., Thangaraju, M., and Ganapathy, V. (2013). The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function. Biochem. J. 450, 169-178. doi: 10.1042/BJ20121248
22. D'Avolio, A., Ciancio, A., Siccardi, M., Smedile, A., Simiele, M., Cusato, J.,et al. (2012). Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ther. Drug Monit. 34, 722-728. doi: 10.1097/FTD.0b013e318272e55a
23. Damaraju, V. L., Mowles, D., Yao, S., Ng, A., Young, J. D., Cass, C. E.,et al. (2012). Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids 31, 236-255. doi: 10.1080/15257770.2011.652330
24. De Clercq, E., and Holy, A. (2005). Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4, 928-940. doi: 10.1038/nrd1877
25. Del Santo, B., Tarafa, G., Felipe, A., Casado, F. J., and Pastor-Anglada, M. (2001). Developmental regulation of the concentrative nucleoside transporters CNT1 and CNT2 in rat liver. J. Hepatol. 34, 873-880. doi: 10.1016/S0168-8278(01)00036-8
26. del Santo, B., Valdes, R., Mata, J., Felipe, A., Casado, F. J., and Pastor-Anglada, M. (1998). Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells. Hepatology 28, 1504-1511. doi: 10.1002/hep.510280609
27. Doehring, A., Hofmann, W. P., Schlecker, C., Zeuzem, S., Sarrazin, C., Berg, T.,et al. (2011). Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenet. Genomics 21, 289-296. doi: 10.1097/FPC.0b013e32834412e7
28. Dragan, Y., Valdes, R., Gomez-Angelats, M., Felipe, A., Javier Casado, F., Pitot, H.,et al. (2000). Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology 32, 239-246. doi: 10.1053/jhep.2000.9546
29. Duflot, S., Riera, B., Fernandez-Veledo, S., Casado, V., Norman, R. I., Casado, F. J.,et al. (2004). ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors. Mol. Cell. Biol. 24, 2710-2719. doi: 10.1128/MCB.24.7.2710-2719.2004
30. Elion, G. B. (1989). Nobel lecture in physiology or medicine-1988. The purine path to chemotherapy. In Vitro Cell. Dev. Biol. 25, 321-330. doi: 10.1007/BF02624593
31. Endo, Y., Obata, T., Murata, D., Ito, M., Sakamoto, K., Fukushima, M.,et al. (2007). Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. Cancer Sci. 98, 1633-1637. doi: 10.1111/j.1349-7006.2007.00581.x
32. Errasti-Murugarren, E., Cano-Soldado, P., Pastor-Anglada, M., and Casado, F. J. (2008). Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodium-binding capacity. Mol. Pharmacol. 73, 379-386. doi: 10.1124/mol.107.041848
33. Errasti-Murugarren, E., Molina-Arcas, M., Casado, F. J., and Pastor-Anglada, M. (2010). The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs. Mol. Pharmacol. 78, 157-165. doi: 10.1124/mol.110.063552
34. Errasti-Murugarren, E., and Pastor-Anglada, M. (2010). Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics 11, 809-841. doi: 10.2217/pgs.10.70
35. Errasti-Murugarren, E., Pastor-Anglada, M., and Casado, F. J. (2007). Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. J. Physiol. 582, 1249-1260. doi: 10.1113/jphysiol.2007.130138
36. Farre, X., Guillen-Gomez, E., Sanchez, L., Hardisson, D., Plaza, Y., Lloberas, J.,et al. (2004). Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int. J. Cancer 112, 959-966. doi: 10.1002/ijc.20524
37. Farrell, J. J., Elsaleh, H., Garcia, M., Lai, R., Ammar, A., Regine, W. F.,et al. (2009). Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136, 187-195. doi: 10.1053/j.gastro.2008.09.067
38. Fernandez-Veledo, S., Jover, R., Casado, F. J., Gomez-Lechon, M. J., and Pastor-Anglada, M. (2007). Transcription factors involved in the expression of SLC28 genes in human liver parenchymal cells. Biochem. Biophys. Res. Commun. 353, 381-388. doi: 10.1016/j.bbrc.2006.12.021
39. Fisher, S. B., Fisher, K. E., Patel, S. H., Lim, M. G., Kooby, D. A., El-Rayes, B. F.,et al. (2013a). Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. Cancer 119, 454-462. doi: 10.1002/cncr.27739
40. Fisher, S. B., Patel, S. H., Bagci, P., Kooby, D. A., El-Rayes, B. F., Staley, C. A.,et al. (2013b). An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer 119, 445-453. doi: 10.1002/cncr.27619
41. Fotoohi, A. K., Lindqvist, M., Peterson, C., and Albertioni, F. (2006). Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem. Biophys. Res. Commun. 343, 208-215. doi: 10.1016/j.bbrc.2006.02.134
42. Frei, P., Biedermann, L., Nielsen, O. H., and Rogler, G. (2013). Use of thiopurines in inflammatory bowel disease. World J. Gastroenterol. 19, 1040-1048. doi: 10.3748/wjg.v19.i7.1040
43. Friedman, A. B., Sparrow, M. P., and Gibson, P. R. (2014). The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. Int. J. Rheum. Dis. 17, 132-141. doi: 10.1111/1756-185X.12204
44. Fujita, H., Ohuchida, K., Mizumoto, K., Itaba, S., Ito, T., Nakata, K.,et al. (2010). Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12, 807-817.
45. Fukuchi, Y., Furihata, T., Hashizume, M., Iikura, M., and Chiba, K. (2010). Characterization of ribavirin uptake systems in human hepatocytes. J. Hepatol. 52, 486-492. doi: 10.1016/j.jhep.2010.01.011
46. Furihata, T., Matsumoto, S., Fu, Z., Tsubota, A., Sun, Y., Kobayashi, K.,et al. (2014). Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob. Agents Chemother. 58, 4555-4564. doi: 10.1128/AAC.02724-14
47. Ganapathy, M. E., Huang, W., Wang, H., Ganapathy, V., and Leibach, F. H. (1998). Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246, 470-475. doi: 10.1006/bbrc.1998.8628
48. Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S.,et al. (2006). Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66, 3928-3935. doi: 10.1158/0008-5472.CAN-05-4203
49. Gloeckner-Hofmann, K., Guillen-Gomez, E., Schmidtgen, C., Porstmann, R., Ziegler, R., Stoss, O.,et al. (2006). Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 70, 238-244. doi: 10.1159/000094541
50. Godoy, V., Banales, J. M., Medina, J. F., and Pastor-Anglada, M. (2014). Functional crosstalk between the adenosine transporter CNT3 and purinergic receptors in the biliary epithelia. J. Hepatol. 61, 1337-1343. doi: 10.1016/j.jhep.2014.06.036
51. Gorraitz, E., Pastor-Anglada, M., and Lostao, M. P. (2010). Effects of Na+ and H+ on steady-state and presteady-state currents of the human concentrative nucleoside transporter 3 (hCNT3). Pflugers Arch. 460, 617-632. doi: 10.1007/s00424-010-0846-9
52. Govindarajan, R., Endres, C. J., Whittington, D., LeCluyse, E., Pastor-Anglada, M., Tse, C. M.,et al. (2008). Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G570-G580. doi: 10.1152/ajpgi.00542.2007
53. Govindarajan, R., Leung, G. P., Zhou, M., Tse, C. M., Wang, J., and Unadkat, J. D. (2009). Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G910-G922. doi: 10.1152/ajpgi.90672.2008
54. Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F.,et al. (2014). Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J. Natl. Cancer Inst. 106, djt347. doi: 10.1093/jnci/djt347
55. Grundemann, D., Schechinger, B., Rappold, G. A., and Schomig, E. (1998). Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci. 1, 349-351. doi: 10.1038/1557
56. Grundemann, D., and Schomig, E. (2000). Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Hum. Genet. 106, 627-635. doi: 10.1007/s004390000309
57. Guillen-Gomez, E., Calbet, M., Casado, J., de Lecea, L., Soriano, E., Pastor-Anglada, M.,et al. (2004). Distribution of CNT2 and ENT1 transcripts in rat brain: selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats. J. Neurochem. 90, 883-893. doi: 10.1111/j.1471-4159.2004.02545.x
58. Guillen-Gomez, E., Pinilla-Macua, I., Perez-Torras, S., Choi, D. S., Arce, Y., Ballarin, J. A.,et al. (2012). New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J. Cell. Physiol. 227, 1521-1528. doi: 10.1002/jcp.22869
59. Hatanaka, T., Haramura, M., Fei, Y.-J., Miyauchi, S., Bridges, C. C., Ganapathy, P. S.,et al. (2004). Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J. Pharmacol. Exp. Ther. 308, 1138-1147. doi: 10.1124/jpet.103.057109
60. Hsu, C. L., Lin, W., Seshasayee, D., Chen, Y. H., Ding, X., Lin, Z.,et al. (2012). Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis. Science 335, 89-92. doi: 10.1126/science.1213682
61. Hu, H., Endres, C. J., Chang, C., Umapathy, N. S., Lee, E. W., Fei, Y. J.,et al. (2006). Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol. Pharmacol. 69, 1542-1553. doi: 10.1124/mol.105.018945
62. Huber-Ruano, I., Errasti-Murugarren, E., Godoy, V., Vera, A., Andreu, A. L., Garcia-Arumi, E.,et al. (2012). Functional outcome of a novel SLC29A3 mutation identified in a patient with H syndrome. Biochem. Biophys. Res. Commun. 428, 532-537. doi: 10.1016/j.bbrc.2012.09.143
63. Huber-Ruano, I., and Pastor-Anglada, M. (2009). Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity. Curr. Drug Metab. 10, 347-358. doi: 10.2174/138920009788499030
64. Jarvis, S. M., Thorn, J. A., and Glue, P. (1998). Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br. J. Pharmacol. 123, 1587-1592. doi: 10.1038/sj.bjp.0701775
65. Jordheim, L. P., Durantel, D., Zoulim, F., and Dumontet, C. (2013). Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 12, 447-464. doi: 10.1038/nrd4010
66. Jung, N., Lehmann, C., Rubbert, A., Knispel, M., Hartmann, P., van Lunzen, J.,et al. (2008). Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab. Dispos. 36, 1616-1623. doi: 10.1124/dmd.108.020826
67. Kang, N., Jun, A. H., Bhutia, Y. D., Kannan, N., Unadkat, J. D., and Govindarajan, R. (2010). Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J. Biol. Chem. 285, 28343-28352. doi: 10.1074/jbc. M110.109199
68. Kawada, N., Uehara, H., Katayama, K., Nakamura, S., Takahashi, H., Ohigashi, H.,et al. (2012). Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J. Hepatobiliary Pancreat. Sci. 19, 717-722. doi: 10.1007/s00534-012-0514-x
69. Kim, R., Tan, A., Lai, K. K., Jiang, J., Wang, Y., Rybicki, L. A.,et al. (2011). Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 117, 3126-3134. doi: 10.1002/cncr.25883
70. Kim, S. R., Saito, Y., Maekawa, K., Sugiyama, E., Kaniwa, N., Ueno, H.,et al. (2006). Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab. Pharmacokinet. 21, 248-256. doi: 10.2133/dmpk.21.248
71. King, K. M., Damaraju, V. L., Vickers, M. F., Yao, S. Y., Lang, T., Tackaberry, T. E.,et al. (2006). A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol. Pharmacol. 69, 346-353.
72. Kobayashi, H., Murakami, Y., Uemura, K., Sudo, T., Hashimoto, Y., Kondo, N.,et al. (2012). Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann. Surg. 256, 288-296. doi: 10.1097/SLA.0b013e3182536a42
73. Kobayashi, Y., Ohshiro, N., Sakai, R., Ohbayashi, M., Kohyama, N., and Yamamoto, T. (2005). Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J. Pharm. Pharmacol. 57, 573-578.
74. Koehler, M. R., Wissinger, B., Gorboulev, V., Koepsell, H., and Schmid, M. (1997). The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenet. Cell Genet. 79, 198-200. doi: 10.1159/000134720
75. Koepsell, H. (2013). The SLC22 family with transporters of organic cations, anions and zwitterions. Mol. Aspects Med. 34, 413-435. doi: 10.1016/j.mam.2012.10.010
76. Koepsell, H., Schmitt, B. M., and Gorboulev, V. (2003). Organic cation transporters. Rev. Physiol. Biochem. Pharmacol. 150, 36-90. doi: 10.1007/s10254-003-0017-x
77. Kondo, N., Murakami, Y., Uemura, K., Sudo, T., Hashimoto, Y., Nakashima, A.,et al. (2012). Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. Ann. Surg. Oncol. 19(Suppl. 3), S646-S655. doi: 10.1245/s10434-011-2140-2
78. Lacoste, C., Herve, J., Bou Nader, M., Dos Santos, A., Moniaux, N., Valogne, Y.,et al. (2012). Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. Cancer Res. 72, 5505-5515. doi: 10.1158/0008-5472.CAN-12-0516
79. Lai, Y., Bakken, A. H., and Unadkat, J. D. (2002). Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies. J. Biol. Chem. 277, 37711-37717. doi: 10.1074/jbc. M204986200
80. Lane, J., Martin, T. A., McGuigan, C., Mason, M. D., and Jiang, W. G. (2010). The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. J. Exp. Ther. Oncol. 8, 203-210.
81. Lang, T. T., Selner, M., Young, J. D., and Cass, C. E. (2001). Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Mol. Pharmacol. 60, 1143-1152.
82. Lee, Y., Koay, E. J., Zhang, W., Qin, L., Kirui, D. K., Hussain, F.,et al. (2014). Human equilibrative nucleoside transporter-1 knockdown tunes cellular mechanics through epithelial-mesenchymal transition in pancreatic cancer cells. PLoS ONE 9:e107973. doi: 10.1371/journal.pone.0107973
83. Mackey, J. R., Yao, S. Y., Smith, K. M., Karpinski, E., Baldwin, S. A., Cass, C. E.,et al. (1999). Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J. Natl. Cancer Inst. 91, 1876-1881. doi: 10.1093/jnci/91.21.1876
84. Mangravite, L. M., Lipschutz, J. H., Mostov, K. E., and Giacomini, K. M. (2001). Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell line. Am. J. Physiol. Renal Physiol. 280, F879-F885.
85. Mangravite, L. M., Xiao, G., and Giacomini, K. M. (2003). Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. Am. J. Physiol. Renal Physiol. 284, F902-F910. doi: 10.1152/ajprenal.00215.2002
86. Marce, S., Molina-Arcas, M., Villamor, N., Casado, F. J., Campo, E., Pastor-Anglada, M.,et al. (2006). Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91, 895-902.
87. Maréchal, R., Bachet, J. B., Mackey, J. R., Dalban, C., Demetter, P., Graham, K.,et al. (2012). Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143, 664-674.e1-e6. doi: 10.1053/j.gastro.2012.06.006
88. Maréchal, R., Mackey, J. R., Lai, R., Demetter, P., Peeters, M., Polus, M.,et al. (2009). Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15, 2913-2919. doi: 10.1158/1078-0432.CCR-08-2080
89. Martinez-Becerra, P., Vaquero, J., Romero, M. R., Lozano, E., Anadon, C., Macias, R. I.,et al. (2012). No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol. Pharm. 9, 1693-1704. doi: 10.1021/mp300028a
90. Mata, J. F., García-Manteiga, J. M., Lostao, M. P., Fernández-Veledo, S., Guillén-Gómez, E., Larrayoz, I. M.,et al. (2001). Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol. Pharmacol. 59, 1542-1548. doi: 10.1124/mol.59.6.1542
91. Matsumura, N., Nakamura, Y., Kohjimoto, Y., Inagaki, T., Nanpo, Y., Yasuoka, H.,et al. (2011). The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int. 108, E110-E116. doi: 10.1111/j.1464-410X.2010.09932.x
92. Medina-Pulido, L., Molina-Arcas, M., Justicia, C., Soriano, E., Burgaya, F., Planas, A. M.,et al. (2013). Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2 in differentiated neuronal PC12 cells. Biochem. J. 454, 437-445. doi: 10.1042/BJ20130231
93. Mey, V., Giovannetti, E., De Braud, F., Nannizzi, S., Curigliano, G., Verweij, F.,et al. (2006). In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br. J. Cancer 95, 289-297. doi: 10.1038/sj.bjc.6603242
94. Minuesa, G., Huber-Ruano, I., Pastor-Anglada, M., Koepsell, H., Clotet, B., and Martinez-Picado, J. (2011). Drug uptake transporters in antiretroviral therapy. Pharmacol. Ther. 132, 268-279. doi: 10.1016/j.pharmthera.2011.06.007
95. Minuesa, G., Purcet, S., Erkizia, I., Molina-Arcas, M., Bofill, M., Izquierdo-Useros, N.,et al. (2008). Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J. Pharmacol. Exp. Ther. 324, 558-567. doi: 10.1124/jpet.107.131482
96. Minuesa, G., Volk, C., Molina-Arcas, M., Gorboulev, V., Erkizia, I., Arndt, P.,et al. (2009). Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J. Pharmacol. Exp. Ther. 329, 252-261. doi: 10.1124/jpet.108.146225
97. Mohelnikova-Duchonova, B., Brynychova, V., Hlavac, V., Kocik, M., Oliverius, M., Hlavsa, J.,et al. (2013). The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemother. Pharmacol. 72, 669-682. doi: 10.1007/s00280-013-2246-2
98. Molho-Pessach, V., Lerer, I., Abeliovich, D., Agha, Z., Abu Libdeh, A., Broshtilova, V.,et al. (2008). The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am. J. Hum. Genet. 83, 529-534. doi: 10.1016/j.ajhg.2008.09.013
99. Molho-Pessach, V., Ramot, Y., Camille, F., Doviner, V., Babay, S., Luis, S. J.,et al. (2014). H syndrome: the first 79 patients. J. Am. Acad. Dermatol. 70, 80-88. doi: 10.1016/j.jaad.2013.09.019
100. Molina-Arcas, M., Bellosillo, B., Casado, F. J., Montserrat, E., Gil, J., Colomer, D.,et al. (2003). Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 101, 2328-2334. doi: 10.1182/blood-2002-07-2236
101. Molina-Arcas, M., Casado, F. J., and Pastor-Anglada, M. (2009). Nucleoside transporter proteins. Curr. Vasc. Pharmacol. 7, 426-434. doi: 10.2174/157016109789043892
102. Molina-Arcas, M., Marce, S., Villamor, N., Huber-Ruano, I., Casado, F. J., Bellosillo, B.,et al. (2005). Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19, 64-68.
103. Molina-Arcas, M., Moreno-Bueno, G., Cano-Soldado, P., Hernandez-Vargas, H., Casado, F. J., Palacios, J.,et al. (2006). Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells. Biochem. Pharmacol. 72, 1646-1656. doi: 10.1016/j.bcp.2006.07.036
104. Molina-Arcas, M., and Pastor-Anglada, M. (2013). "Nucleoside transporters (SLC28 and SLC29) family," in Pharmacogenomics of Drug Transporters, eds T. Ishikawa, R. B. Kim, J. König (Hoboken, NJ: John Wiley & Sons, Inc), 243-270. doi: 10.1002/9781118353240.ch11
105. Morgan, N. V., Morris, M. R., Cangul, H., Gleeson, D., Straatman-Iwanowska, A., Davies, N.,et al. (2010). Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 6:e1000833. doi: 10.1371/journal.pgen.1000833
106. Mori, R., Ishikawa, T., Ichikawa, Y., Taniguchi, K., Matsuyama, R., Ueda, M.,et al. (2007). Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol. Rep. 17, 1201-1205.
107. Morinaga, S., Nakamura, Y., Watanabe, T., Mikayama, H., Tamagawa, H., Yamamoto, N.,et al. (2012). Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann. Surg. Oncol. 19(Suppl. 3), S558-S564. doi: 10.1245/s10434-011-2054-z
108. Muller, J., Lips, K. S., Metzner, L., Neubert, R. H., Koepsell, H., and Brandsch, M. (2005). Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem. Pharmacol. 70, 1851-1860. doi: 10.1016/j.bcp.2005.09.011
109. Murata, A., Amano, R., Yamada, N., Kimura, K., Yashiro, M., Nakata, B.,et al. (2013). Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. World J. Surg. Oncol. 11, 117. doi: 10.1186/1477-7819-11-117
110. Murata, Y., Hamada, T., Kishiwada, M., Ohsawa, I., Mizuno, S., Usui, M.,et al. (2012). Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J. Hepatobiliary Pancreat. Sci. 19, 413-425. doi: 10.1007/s00534-011-0440-3
111. Myers, S. N., Goyal, R. K., Roy, J. D., Fairfull, L. D., Wilson, J. W., and Ferrell, R. E. (2006). Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics 16, 315-320. doi: 10.1097/01.fpc.0000189804.41962.15
112. Nakagawa, N., Murakami, Y., Uemura, K., Sudo, T., Hashimoto, Y., Kondo, N.,et al. (2013). Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 153, 565-575. doi: 10.1016/j.surg.2012.10.010
113. Nies, A. T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R.,et al. (2009). Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50, 1227-1240. doi: 10.1002/hep.23103
114. Oguri, T., Achiwa, H., Muramatsu, H., Ozasa, H., Sato, S., Shimizu, S.,et al. (2007). The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 256, 112-119. doi: 10.1016/j.canlet.2007.06.012
115. Okazaki, T., Javle, M., Tanaka, M., Abbruzzese, J. L., and Li, D. (2010). Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res. 16, 320-329. doi: 10.1158/1078-0432.CCR-09-1555
116. Ormanns, S., Heinemann, V., Raponi, M., Isaacson, J., Laubender, R. P., Haas, M.,et al. (2014). Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur. J. Cancer 50, 1891-1899. doi: 10.1016/j.ejca.2014.04.023
117. Osato, D. H., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Wang, J.,et al. (2003). Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13, 297-301. doi: 10.1097/00008571-200305000-00010
118. Osses, N., Pearson, J. D., Yudilevich, D. L., and Jarvis, S. M. (1996). Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter. Biochem. J. 317, 843-848.
119. Owen, R. P., Lagpacan, L. L., Taylor, T. R., De La Cruz, M., Huang, C. C., Kawamoto, M.,et al. (2006). Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab. Dispos. 34, 12-15. doi: 10.1124/dmd.105.006270
120. Parker, W. B. (2009). Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem. Rev. 109, 2880-2893. doi: 10.1021/cr900028p
121. Pastor-Anglada, M., Molina-Arcas, M., Cano-Soldado, P., and Casado, F. J. (2009). "Biochemistry, physiology and pharmacology of nucleoside and nucleobase transporters," in Transporters as Drugs Carriers, ed. G. C. Ecker (Weinheim: Wiley-VCH), 49-80. doi: 10.1002/9783527627424.ch2
122. Patil, S. D., Ngo, L. Y., Glue, P., and Unadkat, J. D. (1998). Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm. Res. 15, 950-952.
123. Perez-Torras, S., Garcia-Manteiga, J., Mercade, E., Casado, F. J., Carbo, N., Pastor-Anglada, M.,et al. (2008). Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem. Pharmacol. 76, 322-329. doi: 10.1016/j.bcp.2008.05.011
124. Perez-Torras, S., Vidal-Pla, A., Cano-Soldado, P., Huber-Ruano, I., Mazo, A., and Pastor-Anglada, M. (2013). Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner. Cell Death Dis. 4:e648. doi: 10.1038/cddis.2013.173
125. Perrone, G., Morini, S., Santini, D., Rabitti, C., Vincenzi, B., Alloni, R.,et al. (2010). Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. Eur. J. Histochem. 54:e38. doi: 10.4081/ejh.2010.e38
126. Pinilla-Macua, I., Fernandez-Calotti, P., Perez-Del-Pulgar, S., and Pastor-Anglada, M. (2014). Ribavirin uptake into human hepatocyte HHL5 cells is enhanced by interferon-alpha via up-regulation of the human concentrative nucleoside transporter (hCNT2). Mol. Pharm. 11, 3223-3230. doi: 10.1021/mp500263p
127. Prasad, B., Evers, R., Gupta, A., Hop, C. E., Salphati, L., Shukla, S.,et al. (2014). Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab. Dispos. 42, 78-88. doi: 10.1124/dmd.113.053819
128. Prus, K. L., Averett, D. R., and Zimmerman, T. P. (1990). Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res. 50, 1817-1821.
129. Quashie, N. B., Ranford-Cartwright, L. C., and de Koning, H. P. (2010). Uptake of purines in Plasmodium falciparum-infected human erythrocytes is mostly mediated by the human equilibrative nucleoside transporter and the human facilitative nucleobase transporter. Malar. J. 9:36. doi: 10.1186/1475-2875-9-36
130. Rau, M., Stickel, F., Russmann, S., Manser, C. N., Becker, P. P., Weisskopf, M.,et al. (2013). Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J. Hepatol. 58, 669-675. doi: 10.1016/j.jhep.2012.11.027
131. Ritzel, M. W., Ng, A. M., Yao, S. Y., Graham, K., Loewen, S. K., Smith, K. M.,et al. (2001). Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol. Membr. Biol. 18, 65-72. doi: 10.1080/09687680118530
132. Ritzel, M. W., Yao, S. Y., Ng, A. M., Mackey, J. R., Cass, C. E., and Young, J. D. (1998). Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol. Membr. Biol. 15, 203-211.
133. Rius, M., Stresemann, C., Keller, D., Brom, M., Schirrmacher, E., Keppler, D.,et al. (2009). Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol. Cancer. Ther. 8, 225-231. doi: 10.1158/1535-7163.MCT-08-0743
134. Rizwan, A. N., and Burckhardt, G. (2007). Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res. 24, 450-470. doi: 10.1007/s11095-006-9181-4
135. Rizzieri, D., Vey, N., Thomas, X., Huguet-Rigal, F., Schlenk, R. F., Krauter, J.,et al. (2014). A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leuk. Lymphoma 55, 2114-2119. doi: 10.3109/10428194.2013.867489
136. Sakamoto, A., Matsumaru, T., Yamamura, N., Uchida, Y., Tachikawa, M., Ohtsuki, S.,et al. (2013). Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J. Pharm. Sci. 102, 3395-3406. doi: 10.1002/jps.23606
137. Santini, D., Perrone, G., Vincenzi, B., Lai, R., Cass, C., Alloni, R.,et al. (2008). Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann. Oncol. 19, 724-728. doi: 10.1093/annonc/mdm576
138. Santini, D., Schiavon, G., Vincenzi, B., Cass, C. E., Vasile, E., Manazza, A. D.,et al. (2011). Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr. Cancer Drug. Targets 11, 123-129. doi: 10.2174/156800911793743600
139. Santini, D., Vincenzi, B., Fratto, M. E., Perrone, G., Lai, R., Catalano, V.,et al. (2010). Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J. Cell. Physiol. 223, 384-388. doi: 10.1002/jcp.22045
140. Smith, K. M., Ng, A. M., Yao, S. Y., Labedz, K. A., Knaus, E. E., Wiebe, L. I.,et al. (2004). Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J. Physiol. 558, 807-823. doi: 10.1113/jphysiol.2004.068189
141. Smith, K. M., Slugoski, M. D., Cass, C. E., Baldwin, S. A., Karpinski, E., and Young, J. D. (2007). Cation coupling properties of human concentrative nucleoside transporters hCNT1, hCNT2 and hCNT3. Mol. Membr. Biol. 24, 53-64. doi: 10.1080/09687860600942534
142. Smith, K. M., Slugoski, M. D., Loewen, S. K., Ng, A. M., Yao, S. Y., Chen, X. Z.,et al. (2005). The broadly selective human Na+/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. J. Biol. Chem. 280, 25436-25449. doi: 10.1074/jbc. M409454200
143. Spiegel, R., Cliffe, S. T., Buckley, M. F., Crow, Y. J., Urquhart, J., Horovitz, Y.,et al. (2010). Expanding the clinical spectrum of SLC29A3 gene defects. Eur. J. Med. Genet. 53, 309-313. doi: 10.1016/j.ejmg.2010.06.012
144. Spratlin, J., Sangha, R., Glubrecht, D., Dabbagh, L., Young, J. D., Dumontet, C.,et al. (2004). The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10, 6956-6961. doi: 10.1158/1078-0432.CCR-04-0224
145. Sugawara, M., Huang, W., Fei, Y. J., Leibach, F. H., Ganapathy, V., and Ganapathy, M. E. (2000). Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89, 781-789. doi: 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7
146. Svrcek, M., Cros, J., Marechal, R., Bachet, J. B., Flejou, J. F., and Demetter, P. (2014). hENT1 testing in pancreatic ductal adenocarcinoma: a comparison between the murine and the rabbit antibodies. Histopathology. doi: 10.1111/his.12577 [Epub ahead of print].
147. Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Kobayashi, Y., Yamamoto, T.,et al. (2002). Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300, 918-924. doi: 10.1124/jpet.300.3.918
148. Tanaka, T., Doe, J. M., Horstmann, S. A., Ahmad, S., Ahmad, A., Min, S. J.,et al. (2014). Neuroendocrine signaling via the serotonin transporter regulates clearance of apoptotic cells. J. Biol. Chem. 289, 10466-10475. doi: 10.1074/jbc. M113.482299
149. Umapathy, N. S., Ganapathy, V., and Ganapathy, M. E. (2004). Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm. Res. 21, 1303-1310.
150. Uwai, Y., Ida, H., Tsuji, Y., Katsura, T., and Inui, K. (2007). Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24, 811-815. doi: 10.1007/s11095-006-9196-x
151. Valdes, R., Fernandez-Veledo, S., Aymerich, I., Casado, F. J., and Pastor-Anglada, M. (2006). TGF-beta transcriptionally activates the gene encoding the high-affinity adenosine transporter CNT2 in rat liver parenchymal cells. Cell. Mol. Life Sci. 63, 2527-2537. doi: 10.1007/s00018-006-6240-2
152. VanWert, A. L., Gionfriddo, M. R., and Sweet, D. H. (2010). Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm. Drug Dispos. 31, 1-71. doi: 10.1002/bdd.693
153. Visser, F., Vickers, M. F., Ng, A. M., Baldwin, S. A., Young, J. D., and Cass, C. E. (2002). Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J. Biol. Chem. 277, 395-401. doi: 10.1074/jbc. M105324200
154. Volonte, C., and D'Ambrosi, N. (2009). Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J. 276, 318-329. doi: 10.1111/j.1742-4658.2008.06793.x
155. Wallace, L. J., Candlish, D., and De Koning, H. P. (2002). Different substrate recognition motifs of human and trypanosome nucleobase transporters. Selective uptake of purine antimetabolites. J. Biol. Chem. 277, 26149-26156. doi: 10.1074/jbc. M202835200
156. Wiley, J. S., Smith, C. L., and Jamieson, G. P. (1991). Transport of 2'-deoxycoformycin in human leukemic and lymphoma cells. Biochem. Pharmacol. 42, 708-710.
157. Xiao, J. C., Zhang, T. P., and Zhao, Y. P. (2013). Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer. Hepatogastroenterology 60, 258-262. doi: 10.5754/hge12687
158. Xu, Q., Wang, C., Meng, Q., Liu, Q., Sun, H., Peng, J.,et al. (2013). OAT1 and OAT3: Targets of drug-drug interaction between entecavir and JBP485. Eur. J. Pharm. Sci. 48, 650-657. doi: 10.1016/j.ejps.2012.12.024
159. Xu, Q., Wang, C., Meng, Q., Liu, Q., Sun, P., Sun, H.,et al. (2014). The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur. J. Pharm. Sci. 52, 41-47. doi: 10.1016/j.ejps.2013.10.010
160. Yao, S. Y., Ng, A. M., Cass, C. E., Baldwin, S. A., and Young, J. D. (2011). Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J. Biol. Chem. 286, 32552-32562. doi: 10.1074/jbc. M111.236117
161. Yao, S. Y., Ng, A. M., Sundaram, M., Cass, C. E., Baldwin, S. A., and Young, J. D. (2001). Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol. Membr. Biol. 18, 161-167. doi: 10.1080/09687680118681
162. Young, J. D., Yao, S. Y., Sun, L., Cass, C. E., and Baldwin, S. A. (2008). Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 38, 995-1021. doi: 10.1080/00498250801927427
163. Zollner, G., Wagner, M., Fickert, P., Silbert, D., Fuchsbichler, A., Zatloukal, K.,et al. (2005). Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25, 367-379. doi: 10.1111/j.1478-3231.2005.01033.x